Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

• Status: RECRUITING
• Trial end date: 2032-10-31

Summary

This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.

• Phase: PHASE3

Details

• Lead Sponsor: Imunon
• Treatments: Carboplatin; GEN-1; niraparib; olaparib; Paclitaxel